GlassScriptPhysician profile
Lily G Hwang
NPI 1669648986
$88,499.09
in general payments reported to CMS, 2019-2025
40 companies · $13K in 2025
The $13K reported for 2025 was more than what 90% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $1,316 · 2021: $1,468 · 2022: $4,907 · 2023: $19K · 2024: $26K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $37K · Consulting Fee: $11K · Food and Beverage: $7,161 · Travel and Lodging: $2,773 · Education: $216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $37,025.00 |
| Consulting Fee | $10,779.10 |
| Food and Beverage | $7,161.30 |
| Travel and Lodging | $2,773.38 |
| Education | $215.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $44,651.15 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Pfizer INC. | $22,224.97 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $6,644.27 | 2019-2025 | |
| Genentech, INC. | $4,155.10 | 2023-2025 | Xolair |
| Grifols USA, LLC | $2,703.68 | 2022-2025 | Xembify |
| Glaxosmithkline, LLC. | $1,362.46 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $1,245.96 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $721.81 | 2020-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $689.18 | 2020-2025 | Cuvitru, Takhzyro |
| Amgen INC. | $594.03 | 2021-2025 | Tezspire |
| Csl Behring | $428.61 | 2019-2025 | Haegarda, Hizentra |
| Covis Pharma Gmbh | $404.60 | 2019-2023 | |
| Genentech USA, INC. | $344.62 | 2019-2023 | Xolair |
| Teva Pharmaceuticals USA, INC. | $310.43 | 2019-2022 | |
| Biocryst US Sales Co., LLC | $304.00 | 2021-2025 | Orladeyo |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lily Hwang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.